

LIST OF TABLES

2.1	Major modes of liposomal action and related applications	14
2.2	Liposomal products undergoing clinical trials	15
3.1	Calibration curve for the estimation of TRMA	53
3.2	Calibration curves for the estimation of FLU and CLO	54
3.3	Calibration curve for the estimation of PC	57
3.4	Calibration curve for the estimation of CHOL	60
3.5	Composition of various batches of TRMA liposomes with respect to their PC:CHOL and TRMA:PC:CHOL ratios	62
3.6	Composition of various batches of FLU and CLO liposomes with respect to their PC:CHOL and Drug : PC:CHOL ratios	63
3.7	Particle size analysis of selected batches of TRMA liposomes	66
3.8	Details of % drug entrapped, % drug unentrapped and % drug in supernatant during the preparation of liposomal batches of TRMA	69
3.9	Details of % drug entrapped, % drug unentrapped and % drug in supernatant during the preparation of liposomal batches of FLU and CLO	70
3.10	Description of the various gels of TRMA prepared in HPMC K4M gel base	74
3.11	Description of the various formulations of TRMA prepared in different bases	75
3.12	Description of the various formulations of FLU prepared in different bases	76
3.13	Description of the various formulations of CLO prepared in different bases	77
3.14	Data of the stability studies conducted on selected formulations of TRMA-physical observations	80

3.15	Data of the stability studies conducted on selected formulations of TRMA-chemical analysis	81
4.1	Solubility of TRMA, FLU and CLO in pH 7.4 phosphate buffered saline at room temperature	96
4.2	<u>In vitro</u> release profiles of formulations of TRMA in HPMC K4M gel base.	103
4.3	Correlation coefficient and a and b values of the lines of regression for the data of mean cumulative amount released Vs square root of time for formulations of TRMA	110
4.4	Diffusion parameters to assess the release of TRMA from its formulations in HPMC K4M base	117
4.5	Parameters responsible for the effect, side effect and their ratio for formulations of TRMA in HPMC K4M gel base	118
4.6	<u>In vitro</u> release profile of formulations of TRMA in different gel bases	141
4.7	Correlation coefficient and a and b values of the lines of regression for the data of mean cumulative amount released Vs square root of time for formulations of TRMA in different gel bases	144
4.8	Diffusion parameters to assess the release of TRMA from its formulations in different gel bases	146
4.9	Parameters responsible for the effect, side effect and ratio thereof for formulations of TRMA in different gel bases	147
4.10	Rank order variation in the various permeation parameters for plain TRMA and liposomal TRMA formulations using different gel bases	151
4.11	<u>In vitro</u> release profiles of formulations of FLU and CLO	153
4.12	Correlation coefficient and a and b values of the lines of regression for the data of mean cumulative amount released Vs square root of time for formulations of FLU and CLO	156

4.13	Diffusion parameters to assess the release of FLU and CLO from their formulations	160
4.14	Parameters responsible for the effect, side effect and ratio thereof for formulations of FLU and CLO	161
5.1	Setwise division of formulations and bases tested for their skin blanching response	169
5.2	A representative example of how formulations were coded for the skin blanching assay	171
5.3	A representative randomization chart for a volunteer	172
5.4	A representative blanching score card of one observer for a volunteer	173
5.5	% TPS for the skin blanching assay conducted on formulations of Set I	177
5.6	% TPS for the skin blanching assay conducted on formulations of Set II	185
5.7	% TPS for the skin blanching assay conducted on formulations of Set III and Set IV	192
6.1	Changes in the dimensions of keloids following treatment with free CLO gel and liposomal CLO gel	211